Session: Protein Engineering I - Therapeutics (2010 Annual Meeting)

Description:

This session will focus on protein engineering for therapeutic applications with an emphasis on emerging topics and recent successes. Possible areas of interest include, but are not limited to, (1) advances in protein-based therapeutics, (2) proteins for cellular targeting and imaging, abd (3) proteins involved in disease pathology.

Sponsor:

Bioengineering

Chair:

Jennifer A. Maynard
Assistant Professor
University of Texas, Austin
Chemical Engineering
1 University Station, MC 0400
Austin, TX 78712
Phone Number: (512) 471-9188
Fax Number: (512) 471-7060
Email: maynard@che.utexas.edu

Co-Chair:

Bradley C. Bundy
Assistant Professor
Brigham Young University
Chemical Engineering
350S Clyde Building
Provo, UT 84602
Phone Number: 801-422-2807
Email: bundy@byu.edu

Papers:

47a

De Novo Computational Design of Nanobodies and Scfvs
Robert J. Pantazes, The Pennsylvania State University; Costas D. Maranas, The Pennsylvania State University

47b

Novel Technologies for the Detection of Alpha-Synuclein Misfolded Toxic Species
Ahmed M. Kothawala, Rice University; Laura Segatori, Rice University

47c

Calcium Channel Blockers Can Attenuate Amyloid-Beta Self-Assembly: Potential as Dual-Action Drug for Alzheimer's Disease
Jui-Heng Tseng, University of South Carolina; Sukhi K. Guram, University of South Carolina; Melissa A. Moss, University of South Carolina

47d

Engineered Bispecific Proteins That Simultaneously Bind to and Inhibit Both VEGFR2 and Alphav Beta3 Integrin for Cancer Therapy and Diagnosis
Niv Papo, Stanford University; Adam P. Silverman, Stanford University; Jennifer R. Cochran, Stanford University

Intermission

47e

Genetically Engineered Alginate Lyase for the Treatment of Bacterial Biofilms
John W. Lamppa, Dartmouth College; Margaret E. Ackerman, MIT; Jennifer Lai, MIT; Thomas C. Scanlon, Dartmouth College; Karl E. Griswold, Dartmouth College

47f

Mucosal Immunization Utilizing An Engineered Targeting Ligand
Tarik A. Khan, The University of Texas at Austin; Jennifer A. Maynard, The University of Texas at Austin

47g

An Influenza A/H1N1/2009 Hemagglutinin Vaccine Produced in Escherichia Coli
J. Manuel Aguilar-Yáñez, Tecnológico de Monterrey at Monterrey; Rebecca María Dubois, St. Jude Childrenxs Research Hospital; Gonzalo Ismael Mendoza-Ochoa, Tecnológico de Monterrey at Monterrey; Sergio García-Echauri, Tecnológico de Monterrey at Monterrey; Roberto Portillo-Lara, Tecnológico de Monterrey at Monterrey; David Bulnes-Abundis, Tecnológico de Monterrey at Monterrey; Felipe López-Pacheco, Tecnológico de Monterrey at Monterrey; Stacey Schultz-Cherry, St. Jude Childrenxs Research Hospital; Stephen White, St. Jude Childrenxs Research Hospital; Charles Russell, St. Jude Childrenxs Research Hospital; Mario M. Alvarez, Tecnológico de Monterrey at Monterrey

See more of this Group/Topical: Food, Pharmaceutical & Bioengineering Division

<< Previous Session | Next Session >>